Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Shoshana T. Miller"'
Autor:
Anas Younes, Susan J. McCall, Pamela Drullinsky, David J. Straus, John F. Gerecitano, Amanda I. Courtien, Carol S. Portlock, Shoshana T. Miller, Craig S. Sauter, Ariela Noy, Maria Lia Palomba, Craig H. Moskowitz, Andrew D. Zelenetz, Matthew J. Matasar, Heiko Schöder, Sean M. Devlin, Anita Kumar
Publikováno v:
Blood. 131(16)
In the postrituximab era, approximately half of the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to auto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be4bff1952e345ab863f6b7693a38970
https://pubmed.ncbi.nlm.nih.gov/29674349
https://pubmed.ncbi.nlm.nih.gov/29674349
Autor:
Elizabeth Budde, Ranjana H. Advani, Richard T. Hoppe, Heiko Schöder, Anita Kumar, Amanda I. Courtien, Paul M. Barr, Joachim Yahalom, Craig H. Moskowitz, Shoshana T. Miller, Gianna N. McArthur, Carla Casulo, Ariela Noy, M. Matasar, Paul A. Hamlin, Pamela Drullinsky, A.J. Moskowitz, Andrew D. Zelenetz, David J. Straus, S.V. Dandapani, Jonathan W. Friedberg, Joanna C. Yang, Connie Lee Batlevi, Louis S. Constine, Robert T. Chen, Anas Younes
Publikováno v:
Hematological Oncology. 35:171-172
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2c1fdd80e816cb2ac84bc32d139c924
https://doi.org/10.1002/hon.2438_30
https://doi.org/10.1002/hon.2438_30
Autor:
S.S. McCall, John F. Gerecitano, Amanda I. Courtien, Anita Kumar, Heiko Schöder, Craig S. Sauter, Shoshana T. Miller, M. Matasar, Pamela Drullinsky, Carol S. Portlock, Craig H. Moskowitz, David J. Straus, Ariela Noy, Maria Lia Palomba, Anas Younes, Andrew D. Zelenetz
Publikováno v:
Hematological Oncology. 35:265-266
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17f2589eacadb33ad43fca02bb1ab4f5
https://doi.org/10.1002/hon.2438_135
https://doi.org/10.1002/hon.2438_135
Autor:
S.V. Dandapani, Paul M. Barr, Craig H. Moskowitz, Pamela Drullinsky, Carol S. Portlock, Steven M. Horwitz, Robert W. Chen, Alison J. Moskowitz, Louis S. Constine, David J. Straus, Ariela Noy, Heiko Schöder, Audrey Hamilton, Ranjana H. Advani, Philip Caron, Maria Lia Palomba, Connie Lee Batlevi, Carla Casulo, Anita Kumar, Lihua E. Budde, Jonathan W. Friedberg, Joanna C. Yang, Anas Younes, Joachim Yahalom, Matthew J. Matasar, Richard T. Hoppe, Andrew D. Zelenetz, John F. Gerecitano, Amanda I. Courtien, Paul A. Hamlin, Shoshana T. Miller, Zhigang Zhang
Publikováno v:
Blood. 130:734-734
Introduction:The combination of brentuximab vedotin (BV) with AVD chemotherapy followed by 30Gy involved-site radiotherapy (ISRT) for the treatment of early stage, unfavorable risk Hodgkin lymphoma (HL) has demonstrated promising efficacy and an acce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::759d2d5b8f8b8c731c28020786b7c39b
https://doi.org/10.1182/blood.v130.suppl_1.734.734
https://doi.org/10.1182/blood.v130.suppl_1.734.734
Autor:
Heiko Schöder, Amanda I. Courtien, Craig S. Sauter, Shoshana T. Miller, Craig H. Moskowitz, Susan J. McCall, Pamela Jo Harris, Stephanie L. Verwys, Anas Younes, Matthew J. Matasar
Publikováno v:
Blood. 128:4198-4198
Background: In the post-rituximab era, half the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response with standard salvage therapy, and are thus ineligible to proceed to consol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6972fb9984ef16a69ba59e2e53d6ec7
https://doi.org/10.1182/blood.v128.22.4198.4198
https://doi.org/10.1182/blood.v128.22.4198.4198